 | • レポートコード：MRC2312MG01770 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、62ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の難治性多発性骨髄腫市場規模と予測を収録しています。・世界の難治性多発性骨髄腫市場：売上、2018年-2023年、2024年-2029年 ・世界の難治性多発性骨髄腫市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の難治性多発性骨髄腫市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「プロテオソーム阻害剤」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 難治性多発性骨髄腫のグローバル主要企業は、Bristol Myers Squibb、 Teva Pharmaceutical Industries Ltd.、 Pfizer Inc.、 Janssen Global Services, LLC、 Gilead Sciences, Inc.、 Fresenius Kabi、 GSK plc.、 Novartis AG、 Takeda Pharmaceutical Company Limited、 Genentech, Inc.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、難治性多発性骨髄腫のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の難治性多発性骨髄腫市場：タイプ別、2018年-2023年、2024年-2029年 世界の難治性多発性骨髄腫市場：タイプ別市場シェア、2022年 ・プロテオソーム阻害剤、免疫調節剤、抗CD38モノクローナル抗体、その他 世界の難治性多発性骨髄腫市場：用途別、2018年-2023年、2024年-2029年 世界の難治性多発性骨髄腫市場：用途別市場シェア、2022年 ・病院、専門診療所、その他 世界の難治性多発性骨髄腫市場：地域・国別、2018年-2023年、2024年-2029年 世界の難治性多発性骨髄腫市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における難治性多発性骨髄腫のグローバル売上、2018年-2023年 ・主要企業における難治性多発性骨髄腫のグローバル売上シェア、2022年 ・主要企業における難治性多発性骨髄腫のグローバル販売量、2018年-2023年 ・主要企業における難治性多発性骨髄腫のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Bristol Myers Squibb、 Teva Pharmaceutical Industries Ltd.、 Pfizer Inc.、 Janssen Global Services, LLC、 Gilead Sciences, Inc.、 Fresenius Kabi、 GSK plc.、 Novartis AG、 Takeda Pharmaceutical Company Limited、 Genentech, Inc. ************************************************************* ・調査・分析レポートの概要 難治性多発性骨髄腫市場の定義 市場セグメント 世界の難治性多発性骨髄腫市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の難治性多発性骨髄腫市場規模 世界の難治性多発性骨髄腫市場規模：2022年 VS 2029年 世界の難治性多発性骨髄腫市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの難治性多発性骨髄腫の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の難治性多発性骨髄腫製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：プロテオソーム阻害剤、免疫調節剤、抗CD38モノクローナル抗体、その他 難治性多発性骨髄腫のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、専門診療所、その他 難治性多発性骨髄腫の用途別グローバル売上・予測 ・地域別市場分析 地域別難治性多発性骨髄腫市場規模 2022年と2029年 地域別難治性多発性骨髄腫売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Bristol Myers Squibb、 Teva Pharmaceutical Industries Ltd.、 Pfizer Inc.、 Janssen Global Services, LLC、 Gilead Sciences, Inc.、 Fresenius Kabi、 GSK plc.、 Novartis AG、 Takeda Pharmaceutical Company Limited、 Genentech, Inc. ... |
This research report provides a comprehensive analysis of the Refractory Multiple Myeloma market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Refractory Multiple Myeloma market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Refractory Multiple Myeloma, challenges faced by the industry, and potential opportunities for market players.
The global Refractory Multiple Myeloma market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Refractory Multiple Myeloma market presents opportunities for various stakeholders, including Hospital, Specialty Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Refractory Multiple Myeloma market. Additionally, the growing consumer demand present avenues for market expansion.
The global Refractory Multiple Myeloma market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Refractory Multiple Myeloma market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Refractory Multiple Myeloma market.
Market Overview: The report provides a comprehensive overview of the Refractory Multiple Myeloma market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Proteosome Inhibitor, Immunomodulators), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Refractory Multiple Myeloma market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Refractory Multiple Myeloma market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Refractory Multiple Myeloma market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Refractory Multiple Myeloma market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Refractory Multiple Myeloma market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Refractory Multiple Myeloma market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Refractory Multiple Myeloma, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Refractory Multiple Myeloma market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Refractory Multiple Myeloma market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Proteosome Inhibitor
Immunomodulators
Anti-CD38 Monoclonal Antibody
Others
Market segment by Application
Hospital
Specialty Clinic
Others
Global Refractory Multiple Myeloma Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Bristol Myers Squibb
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Janssen Global Services, LLC
Gilead Sciences, Inc.
Fresenius Kabi
GSK plc.
Novartis AG
Takeda Pharmaceutical Company Limited
Genentech, Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Refractory Multiple Myeloma, market overview.
Chapter 2: Global Refractory Multiple Myeloma market size in revenue.
Chapter 3: Detailed analysis of Refractory Multiple Myeloma company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Refractory Multiple Myeloma in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Refractory Multiple Myeloma Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Refractory Multiple Myeloma Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Refractory Multiple Myeloma Overall Market Size
2.1 Global Refractory Multiple Myeloma Market Size: 2022 VS 2029
2.2 Global Refractory Multiple Myeloma Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Refractory Multiple Myeloma Players in Global Market
3.2 Top Global Refractory Multiple Myeloma Companies Ranked by Revenue
3.3 Global Refractory Multiple Myeloma Revenue by Companies
3.4 Top 3 and Top 5 Refractory Multiple Myeloma Companies in Global Market, by Revenue in 2022
3.5 Global Companies Refractory Multiple Myeloma Product Type
3.6 Tier 1, Tier 2 and Tier 3 Refractory Multiple Myeloma Players in Global Market
3.6.1 List of Global Tier 1 Refractory Multiple Myeloma Companies
3.6.2 List of Global Tier 2 and Tier 3 Refractory Multiple Myeloma Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Refractory Multiple Myeloma Market Size Markets, 2022 & 2029
4.1.2 Proteosome Inhibitor
4.1.3 Immunomodulators
4.1.4 Anti-CD38 Monoclonal Antibody
4.1.5 Others
4.2 By Type – Global Refractory Multiple Myeloma Revenue & Forecasts
4.2.1 By Type – Global Refractory Multiple Myeloma Revenue, 2018-2023
4.2.2 By Type – Global Refractory Multiple Myeloma Revenue, 2024-2029
4.2.3 By Type – Global Refractory Multiple Myeloma Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Refractory Multiple Myeloma Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Specialty Clinic
5.1.4 Others
5.2 By Application – Global Refractory Multiple Myeloma Revenue & Forecasts
5.2.1 By Application – Global Refractory Multiple Myeloma Revenue, 2018-2023
5.2.2 By Application – Global Refractory Multiple Myeloma Revenue, 2024-2029
5.2.3 By Application – Global Refractory Multiple Myeloma Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Refractory Multiple Myeloma Market Size, 2022 & 2029
6.2 By Region – Global Refractory Multiple Myeloma Revenue & Forecasts
6.2.1 By Region – Global Refractory Multiple Myeloma Revenue, 2018-2023
6.2.2 By Region – Global Refractory Multiple Myeloma Revenue, 2024-2029
6.2.3 By Region – Global Refractory Multiple Myeloma Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Refractory Multiple Myeloma Revenue, 2018-2029
6.3.2 US Refractory Multiple Myeloma Market Size, 2018-2029
6.3.3 Canada Refractory Multiple Myeloma Market Size, 2018-2029
6.3.4 Mexico Refractory Multiple Myeloma Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Refractory Multiple Myeloma Revenue, 2018-2029
6.4.2 Germany Refractory Multiple Myeloma Market Size, 2018-2029
6.4.3 France Refractory Multiple Myeloma Market Size, 2018-2029
6.4.4 U.K. Refractory Multiple Myeloma Market Size, 2018-2029
6.4.5 Italy Refractory Multiple Myeloma Market Size, 2018-2029
6.4.6 Russia Refractory Multiple Myeloma Market Size, 2018-2029
6.4.7 Nordic Countries Refractory Multiple Myeloma Market Size, 2018-2029
6.4.8 Benelux Refractory Multiple Myeloma Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Refractory Multiple Myeloma Revenue, 2018-2029
6.5.2 China Refractory Multiple Myeloma Market Size, 2018-2029
6.5.3 Japan Refractory Multiple Myeloma Market Size, 2018-2029
6.5.4 South Korea Refractory Multiple Myeloma Market Size, 2018-2029
6.5.5 Southeast Asia Refractory Multiple Myeloma Market Size, 2018-2029
6.5.6 India Refractory Multiple Myeloma Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Refractory Multiple Myeloma Revenue, 2018-2029
6.6.2 Brazil Refractory Multiple Myeloma Market Size, 2018-2029
6.6.3 Argentina Refractory Multiple Myeloma Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Refractory Multiple Myeloma Revenue, 2018-2029
6.7.2 Turkey Refractory Multiple Myeloma Market Size, 2018-2029
6.7.3 Israel Refractory Multiple Myeloma Market Size, 2018-2029
6.7.4 Saudi Arabia Refractory Multiple Myeloma Market Size, 2018-2029
6.7.5 UAE Refractory Multiple Myeloma Market Size, 2018-2029
7 Refractory Multiple Myeloma Companies Profiles
7.1 Bristol Myers Squibb
7.1.1 Bristol Myers Squibb Company Summary
7.1.2 Bristol Myers Squibb Business Overview
7.1.3 Bristol Myers Squibb Refractory Multiple Myeloma Major Product Offerings
7.1.4 Bristol Myers Squibb Refractory Multiple Myeloma Revenue in Global Market (2018-2023)
7.1.5 Bristol Myers Squibb Key News & Latest Developments
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Teva Pharmaceutical Industries Ltd. Company Summary
7.2.2 Teva Pharmaceutical Industries Ltd. Business Overview
7.2.3 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Major Product Offerings
7.2.4 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Revenue in Global Market (2018-2023)
7.2.5 Teva Pharmaceutical Industries Ltd. Key News & Latest Developments
7.3 Pfizer Inc.
7.3.1 Pfizer Inc. Company Summary
7.3.2 Pfizer Inc. Business Overview
7.3.3 Pfizer Inc. Refractory Multiple Myeloma Major Product Offerings
7.3.4 Pfizer Inc. Refractory Multiple Myeloma Revenue in Global Market (2018-2023)
7.3.5 Pfizer Inc. Key News & Latest Developments
7.4 Janssen Global Services, LLC
7.4.1 Janssen Global Services, LLC Company Summary
7.4.2 Janssen Global Services, LLC Business Overview
7.4.3 Janssen Global Services, LLC Refractory Multiple Myeloma Major Product Offerings
7.4.4 Janssen Global Services, LLC Refractory Multiple Myeloma Revenue in Global Market (2018-2023)
7.4.5 Janssen Global Services, LLC Key News & Latest Developments
7.5 Gilead Sciences, Inc.
7.5.1 Gilead Sciences, Inc. Company Summary
7.5.2 Gilead Sciences, Inc. Business Overview
7.5.3 Gilead Sciences, Inc. Refractory Multiple Myeloma Major Product Offerings
7.5.4 Gilead Sciences, Inc. Refractory Multiple Myeloma Revenue in Global Market (2018-2023)
7.5.5 Gilead Sciences, Inc. Key News & Latest Developments
7.6 Fresenius Kabi
7.6.1 Fresenius Kabi Company Summary
7.6.2 Fresenius Kabi Business Overview
7.6.3 Fresenius Kabi Refractory Multiple Myeloma Major Product Offerings
7.6.4 Fresenius Kabi Refractory Multiple Myeloma Revenue in Global Market (2018-2023)
7.6.5 Fresenius Kabi Key News & Latest Developments
7.7 GSK plc.
7.7.1 GSK plc. Company Summary
7.7.2 GSK plc. Business Overview
7.7.3 GSK plc. Refractory Multiple Myeloma Major Product Offerings
7.7.4 GSK plc. Refractory Multiple Myeloma Revenue in Global Market (2018-2023)
7.7.5 GSK plc. Key News & Latest Developments
7.8 Novartis AG
7.8.1 Novartis AG Company Summary
7.8.2 Novartis AG Business Overview
7.8.3 Novartis AG Refractory Multiple Myeloma Major Product Offerings
7.8.4 Novartis AG Refractory Multiple Myeloma Revenue in Global Market (2018-2023)
7.8.5 Novartis AG Key News & Latest Developments
7.9 Takeda Pharmaceutical Company Limited
7.9.1 Takeda Pharmaceutical Company Limited Company Summary
7.9.2 Takeda Pharmaceutical Company Limited Business Overview
7.9.3 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Major Product Offerings
7.9.4 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Revenue in Global Market (2018-2023)
7.9.5 Takeda Pharmaceutical Company Limited Key News & Latest Developments
7.10 Genentech, Inc.
7.10.1 Genentech, Inc. Company Summary
7.10.2 Genentech, Inc. Business Overview
7.10.3 Genentech, Inc. Refractory Multiple Myeloma Major Product Offerings
7.10.4 Genentech, Inc. Refractory Multiple Myeloma Revenue in Global Market (2018-2023)
7.10.5 Genentech, Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
